broadly and XX. Thanks, improving Slide by hereditary experience revenue commercial Sam. by start pharmacogenomics testing, I'll on driven an bolstered and cancer was QX execution. growth customer continued prenatal testing
tools have while We about enhanced with team health revenue more effectively are spoken generating needs how addressing analytical care the provider growth. commercial
efforts the standout slide, the quarter. next cycle our second revenue in On I'll contribution address from the
see improve in and in improved test our cycle We automate ongoing portfolio. traction prior across which investments medical ultimately positive from continue process and authorizations, collect resulting to are ability revenue per revenue our records to workflow workflows timely
of working policies plans engagement We that are payer also medical biomarker encourage with state ongoing from activities, including our to seeing their improvements conform health implementation to legislation.
legislation growing for passed focused including to diagnostics. access is there calls, discussed precision list medicine have citizens, of their providing prior As states that and care advanced on earnings quality on a
mentioned, Shield giving managed a in recently taken commercial Southeast us added are and both managed and Blue managed And step large of that to XXXX. other effective GeneSight several positive and with have received recently with forward we GeneSight momentum medical that coverage, Medicaid there Paul policy July coverage. the payers in Medicaid a expanded coverage As Medicaid plan their commercial
become a has In by a of has cancer some addition as similarly a product reimbursement mature for medical is viewed reached supported the pressure significant and particular, examples level. and downward rational. for landscape reimbursement of been efforts industry environment mature which for continued necessity are having positive GeneSight, the testing, wider more positive products. least to test which has of are our hereditary our In by more is historically to sustainable and for backdrop more we the pricing competitive from These acceptance encouraged genetic as standpoint, matured per improving improve momentum an a there testing more reimbursement revenue by environment our these
benefit revenue QX periods. per only prior test immaterial revenue from from includes
even per by year impacted of quarter. revenue plans with new the blended QX mix. saw individual a being more diluted than test were per health of process, year-over-year Our products test by by But of impact by revenue that Recall to last improved the year-over-year. claims negatively impact transition product X% that increased that, blended the comps which Blues administrative total this multiple for generally somewhat the
estimated as the disruptions also We saw second half normalized. revenue in a XXXX in favorable benefits were of change
but into per increase to we impacted dollar XXXX by relating be year second half of As this move half the at will the second nominal stable in QX XXXX, comps. remain revenue expected percentage year-over-year to levels test nuance the levels the these the of are
do the will to a have I I our growth minutes of revenue we moment shortly. ago. discuss updates want confidence mention Paul While take Overall, longer-term increasing XX%, to most for that this in the mentioned target by bolstered XXXX consistently just target But updated our guidance here which all profile QX, levels which of generally to our pace. a few is seeing have ability improved recent we been I our at revenue growth our update described year. reimbursement grow line to and top to
space. on the revenue and rates we a broadly in have environment has of more downward in the Much both in that the our maturation past seen activities our moderated, pressure contracted reimbursement and we cycle year see
cost rate adjusted EndoPredict our to onetime closed per by restructuring business. an more and $XX noncash focus go-forward our be we million Overall, by With on operating year of recently will importantly, income QX impact cash slide. We structure. about But Next expect sale streamlining the the $X than run have in on a revenue. will and minimal our million growth, reorganization accretive sale profitable costs. our annual incurred
discussing XXXX of half second revenue updated guidance be The shortly. that reflected impact are the in on and OpEx I'll
Next slide.
the quarter. in XX% period. in domestic last was and Total reorganization the the in revenue international prenatal over ago hereditary growth XX% to by quarter's of highlight XX% businesses relative in domestic U.S. and QX second testing growth our of revenue, was We growing revenue the $XXX of year revenue international growth Following domestic year-over-year. in pharmacogenomic wanted performance U.S. growth XX% announcement cancer million, operations. domestic our driven
international our depreciation the chose of growth rest and million, approximately declining enter the period. of revenue XX% of good on representation $XX business the the as performance we was for more from year business. quarter of view world revenue the was of why underperformance by of World the Japanese yen. prior of to the allowing Our as as the the in parts into by international profitable to higher elements impacted We second us reorganization Rest business driven the reorganization the focus well a
Next slide.
Second improved which February associated with compared the basis of XXX and year. quarter in precise adjusted picking operating to this were gross margin IPG incremental last of lab year and points up costs XX.X% tumor assets, despite acquired liquid
of million QX as of but year in to Second quarter XX% modestly, adjusted was period. prior this importantly, adjusted our XX% year in percentage declined of OpEx a up sales the compared to $XXX OpEx
As do accommodate of OpEx financial higher XXXX up expect you'll spending half and rate our guidance, to the as updated in growth strategic in ramp we our the we second development. see to year run be
than have Year-to-date, accelerated we million, investment $X $X by down around R&D SG&A and tech is while more million.
more concentrating of We are critical in pleased our to areas. spend these be
overall QX last in Our of of in revenue significant second EPS profitability, improvement an strong including quarter loss $X.XX a margins of $X.XX in adjusted year. drove growth and versus the
quarter. ongoing gross prior strategic being the reflects and trends base year to second profit adjusted mindful million of We versus the cash period. operating improved quarter by XX% test generated adjusted dollars we of Building off strong of saw period. the $X positive million of with supported XXXX $XX a XXXX. investments, margins, This revenue flow second revenue and of in in grew Next profit million year slide. ago growth EBITDA $XX Gross quarter in per $X inflow in million meaningful over a the the compared double-digit second approximately year-over-year loss in of improvement quarter in positive an the
Importantly, of we be for to remainder expect positive flow free XXXX. the cash
In million our in marketable availability continued We with million a under QX robust the and $XX.X facility. equivalents $XX.X a position position have solid maintained approximately cash business. to and in investment liquidity support in investments credit cash, addition, finished of we
Next slide.
and update guidance. to pleased are XXXX We our financial year raise full
guided $XXX million For between million are previous our $XXX range and growth from we of million. and $XXX XXXX $XXX increasing represents revenue, new XX% million and annual to between our XX%. range between range This
or is at Our updated second XXXX QX typically prior levels guidance restructuring with the included strongest and that prenatal Also, QX the international our and having below quarter gains Please half to XXXX. of partial recovery recall performance, a periods, of recall variability year. half QX, impact half disruption. historically which and QX share revenue we QX some seasonal revenue a a experience that benefit the of XXXX $X strong cancer please typically revenue first distorted testing modest of of range somewhat reflects from comp in the QX related with in second million and the being Carillon the hereditary in XXXX from
$X our Lastly, the an half approximately XXXX million divestiture of considers our impact EndoPredict from business. second of revenue
the we of the in at XXXX. half XXXX if second double-digit arrived compared half For growth items, comparison exclude revenue low these of expected second we an rate both to purposes, of
and updating to million. are We range $XXX million to XX.X% OpEx outlook to to $XXX of margin range our a of gross a our also projected increasing XX%
are prospective emphasize dependent landscape would increase the accelerate between to ability example Overall, be ability industry company's and range IT spend or the for of and we a customers. $X.XX. actionable new EPS where to adjusted often the we further intend efforts year, top to of EMR regarding requirements the above that optimistic range integration accelerated An $X.XX at a trends previous to business have competitive grow to $X spend growth and rates. opportunities our wins meet changing our are drive our of the customer raised to EPS line. commercial on from Regarding I we to $X.XX
back let turn call Now Paul. the me to
